Chikungunya virus virus-like particle vaccine (Vimkunya) induces a rapid and durable antigen-specific CD4+ T cell response
T cells were detected as early as eight days post-vaccination, with their frequency increasing over 57 days and stabilizing until 182 days. These results support the rapid induction and durability of the immune response elicited by Vimkunya, thereby supporting this vaccine's potential to provide protection against CHIKV disease.
Authors
- Steven T. Stoddard (ORCID: https://orcid.org/0000-0002-9608-563X)
- E. Alexandar Escarrega
- Lo Vang (ORCID: https://orcid.org/0000-0001-9882-3184)
- Rosa Isela Gálvez (ORCID: https://orcid.org/0000-0002-9320-2570)
- Daniela Weiskopf (ORCID: https://orcid.org/0000-0003-2968-7371)
- Kelly L. Warfield (ORCID: https://orcid.org/0000-0003-1866-5388)
- Rimjhim Agarwal (ORCID: https://orcid.org/0000-0002-6939-5077)
- Christopher S. Morello (ORCID: https://orcid.org/0000-0001-8113-1173)
- Fernanda H. Cortes
- Calvin Ha
- Alba Grifoni
- Alessandro Sette
- John Villalpando
Institutions
- La Jolla Institute for Immunology (US)
- Emergent BioSolutions (United States) (US)
- Bavarian Nordic (United States) (US)
- Fundação Oswaldo Cruz (BR)
Publication Details
- Journal
- Vaccine
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1016/j.vaccine.2026.128548
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institutes of Health